Hello, Fool! | Login | Signup | My Fool
Oct 6, 2008 9:55 PM ET | Feedback | Site Changes | Help
The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.
View All Commentary (HGSI)
Recs
Fergy2b (47.81) Submitted: 8/24/07 7:08 AM : Start Price: $8.72 HGSI Score: -13.46
Oversold recently
Report this Post Replies: 0 | Reply
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK